Fabry : National Initiative of Screening
Not Applicable
Completed
- Conditions
- Ischemic Stroke Hospitalized
- Registration Number
- NCT00484549
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Brief Summary
Fabry disease is a genetic disease due to an enzymatic deficit. A screening of this disease allows patients to benefit from an enzyme replacement therapy and prevent the occurrence of life threatening manifestations such as an ischemic stroke.
The purpose of the study is to determinate the prevalence of Fabry disease in a population of male patients hospitalized for an ischemic stroke.
This study, with a screening of Fabry disease, allows the patients to make a precise diagnosis of their ischemic stroke and to facilitate the screening of the other members at the facility.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 889
Inclusion Criteria
- Hospitalized ischemic stroke
- Written and signed informed consent from patient or legal representative
Exclusion Criteria
- Patients belonging to a family which has a Fabry disease's diagnosis confirmed
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Fabry disease's screening (Positive microdosage confirmed by a macrodosage) Positive microdosage confirmed by a macrodosage
- Secondary Outcome Measures
Name Time Method Describe and compare the characteristics of patients affected by Fabry disease and patients who are not affected Identify clinical and neuroradiological predictive elements of Fabry disease patients affected by Fabry disease
Trial Locations
- Locations (1)
Hôpital Gabriel Montpied
🇫🇷Clermont-Ferrand, France